BioCentury | Apr 29, 2020
Product Development

Highlights from AACR’s first annual virtual meeting show mixed results for I/O combos, promise for new targets, modalities

...that harbor an MLL1 rearrangement. SNDX-5613 is a first-in-class selective inhibitor of Menin-MLL binding interaction. Compugen Ltd....
BioCentury | Jan 8, 2020
Company News

Management tracks: Fred Hutch taps BMS CSO Lynch; plus GSK, Rubius, Provention, Antengene, Revitope, Compugen, Wellington, Adamas, Arcturus and Turnstone

...antibodies, hired Steve Arkinstall as CEO. He was CEO of Elstar Therapeutics Inc. Immuno-oncology company Compugen Ltd....
...at BMS. Elizabeth S. Eaton, Staff Writer Fred Hutchinson Cancer Research Center GlaxoSmithKline plc Provention Bio Inc. Antengene Corp. Revitope Oncology Inc. Compugen Ltd. Wellington...
BioCentury | Oct 19, 2019
Product Development

Tracking the rise and fall of next-generation checkpoint targets for cancer

...PVRIG has been limping along with a single program: COM701 (cgen-15029), an anti-PVRIG mAb from Compugen Ltd....
BioCentury | May 28, 2019
Company News

Management tracks: Atara names Novartis’ Touchon as CEO; plus Intellia, Arch Oncology

...hired Kirk Christoffersen as its first CBO. He was SVP, corporate and business development at Compugen Ltd....
BioCentury | Apr 8, 2019
Company News

Management tracks: WuXi AppTec, Kymab, Acceleron

...Zweifach is co-founder and CEO of Nuvelution Pharma Inc. (Cambridge, Mass.) and board member of Compugen Ltd....
BioCentury | Mar 8, 2019
Company News

Compugen cuts workforce by 35%

...Compugen will reduce headcount by 35 (35%), with cuts coming primarily from R&D. Compugen Ltd. (NASDAQ:CGEN) said...
...is a mAb targeting poliovirus receptor related immunoglobulin domain containing (PVRIG; CD112R). Shannon Lehnbeuter, Staff Writer COM701, cgen-15029 Compugen Ltd....
BioCentury | Oct 12, 2018
Company News

Compugen partners with BMS for Phase I combo trial of its first-in-class checkpoint inhibitor

...new checkpoint target poliovirus receptor related immunoglobulin domain containing (PVRIG; CD112R) (see "Computing Checkpoints" ). Compugen...
...The partners could explore other combinations through other trials, including BMS-sponsored trials, under the deal. Compugen...
...to Compugen's close on Oct. 10 before the partners announced the deal on Oct. 11. Compugen Ltd....
BioCentury | Aug 24, 2018
Targets & Mechanisms

Computing checkpoints

...After 25 years as a discovery company, Compugen Ltd. is about to enter the clinic for the...
...could allow COM701 to work where PD-1 inhibitors don’t. COM701 is a mAb against PVRIG. Compugen...
...checkpoint inhibitors in hand, Compugen then set out to elucidate their functions in preclinical studies. Compugen...
BioCentury | Apr 6, 2018
Company News

MedImmune, Compugen in antibody deal

...plc (LSE:AZN; NYSE:AZN) an exclusive license to develop multiple bi-specific and multi-specific immuno-oncology antibody products. Compugen...
...up to $200 million in milestones for the first product; if additional products are developed, Compugen...
...is also eligible for royalties. MedImmune will be responsible for research, development and commercial activities. Compugen Ltd....
BioCentury | Mar 27, 2018
Company News

Management Tracks: CRISPR, UK Research and Innovation

...Capital, which participated in BeyondSpring's $15.3 million venture round in 2016. Drug target discovery company Compugen Ltd....
Items per page:
1 - 10 of 228
BioCentury | Apr 29, 2020
Product Development

Highlights from AACR’s first annual virtual meeting show mixed results for I/O combos, promise for new targets, modalities

...that harbor an MLL1 rearrangement. SNDX-5613 is a first-in-class selective inhibitor of Menin-MLL binding interaction. Compugen Ltd....
BioCentury | Jan 8, 2020
Company News

Management tracks: Fred Hutch taps BMS CSO Lynch; plus GSK, Rubius, Provention, Antengene, Revitope, Compugen, Wellington, Adamas, Arcturus and Turnstone

...antibodies, hired Steve Arkinstall as CEO. He was CEO of Elstar Therapeutics Inc. Immuno-oncology company Compugen Ltd....
...at BMS. Elizabeth S. Eaton, Staff Writer Fred Hutchinson Cancer Research Center GlaxoSmithKline plc Provention Bio Inc. Antengene Corp. Revitope Oncology Inc. Compugen Ltd. Wellington...
BioCentury | Oct 19, 2019
Product Development

Tracking the rise and fall of next-generation checkpoint targets for cancer

...PVRIG has been limping along with a single program: COM701 (cgen-15029), an anti-PVRIG mAb from Compugen Ltd....
BioCentury | May 28, 2019
Company News

Management tracks: Atara names Novartis’ Touchon as CEO; plus Intellia, Arch Oncology

...hired Kirk Christoffersen as its first CBO. He was SVP, corporate and business development at Compugen Ltd....
BioCentury | Apr 8, 2019
Company News

Management tracks: WuXi AppTec, Kymab, Acceleron

...Zweifach is co-founder and CEO of Nuvelution Pharma Inc. (Cambridge, Mass.) and board member of Compugen Ltd....
BioCentury | Mar 8, 2019
Company News

Compugen cuts workforce by 35%

...Compugen will reduce headcount by 35 (35%), with cuts coming primarily from R&D. Compugen Ltd. (NASDAQ:CGEN) said...
...is a mAb targeting poliovirus receptor related immunoglobulin domain containing (PVRIG; CD112R). Shannon Lehnbeuter, Staff Writer COM701, cgen-15029 Compugen Ltd....
BioCentury | Oct 12, 2018
Company News

Compugen partners with BMS for Phase I combo trial of its first-in-class checkpoint inhibitor

...new checkpoint target poliovirus receptor related immunoglobulin domain containing (PVRIG; CD112R) (see "Computing Checkpoints" ). Compugen...
...The partners could explore other combinations through other trials, including BMS-sponsored trials, under the deal. Compugen...
...to Compugen's close on Oct. 10 before the partners announced the deal on Oct. 11. Compugen Ltd....
BioCentury | Aug 24, 2018
Targets & Mechanisms

Computing checkpoints

...After 25 years as a discovery company, Compugen Ltd. is about to enter the clinic for the...
...could allow COM701 to work where PD-1 inhibitors don’t. COM701 is a mAb against PVRIG. Compugen...
...checkpoint inhibitors in hand, Compugen then set out to elucidate their functions in preclinical studies. Compugen...
BioCentury | Apr 6, 2018
Company News

MedImmune, Compugen in antibody deal

...plc (LSE:AZN; NYSE:AZN) an exclusive license to develop multiple bi-specific and multi-specific immuno-oncology antibody products. Compugen...
...up to $200 million in milestones for the first product; if additional products are developed, Compugen...
...is also eligible for royalties. MedImmune will be responsible for research, development and commercial activities. Compugen Ltd....
BioCentury | Mar 27, 2018
Company News

Management Tracks: CRISPR, UK Research and Innovation

...Capital, which participated in BeyondSpring's $15.3 million venture round in 2016. Drug target discovery company Compugen Ltd....
Items per page:
1 - 10 of 228